Shree Ganesh Biotech
SHREEGANESHBIOTECHINDIALTD NSE
Shree Ganesh Biotech
HealthcareNSE: SHREEGANESHBIOTECHINDIALTD BSE: SHREEGANES Biotechnology
Key Fundamentals
MicrocapBiotechnologyHealthcareMarket Cap
₹19.50 Cr
Volatility
Moderate
P/E Ratio
-49
EBITDA
₹0.50 Cr
Return on Equity
0.59%
Debt to Equity
0
Book Value
₹1.6
EPS
₹0.02
52W High
₹0.8
52W Low
₹0.48
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company is almost debt free.
- Stock is trading at 0.31 times its book value
Weaknesses
5- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -22.0% over past five years.
- Company has a low return on equity of 0.84% over last 3 years.
- Working capital days have increased from 260 days to 861 days
Growth Rate
Revenue Growth
-73.77% lower than
3Y
Net Income Growth
33.33% higher than
3Y
Cash Flow Change
19.69% higher than
3Y
ROE
34.09% higher than
3Y
ROCE
32.79% higher than
3Y
EBITDA Margin (Avg.)
403% higher than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 8.25 | 4.12 | 4.12 | 3.78 | 3.56 | 1.98 | 14.41 | 3.01 | 1.38 | 0.77 | 0.7 | 2.12 | 1.43 |
| Expenses | 8.1 | 4.04 | 4.03 | 4.3 | 3.69 | 1.96 | 13.94 | 4.43 | 1.47 | 1.17 | 0.75 | 2.55 | 2.32 |
| Operating Profit | 0.15 | 0.08 | 0.09 | -0.52 | -0.13 | 0.02 | 0.47 | -1.42 | -0.09 | -0.4 | -0.05 | -0.43 | -0.89 |
| OPM % | 1.82% | 1.94% | 2.18% | -13.76% | -3.65% | 1.01% | 3.26% | -47.18% | -6.52% | -51.95% | -7.14% | -20.28% | -62.24% |
| Other Income | 0 | 0 | 0 | 1.06 | 0.37 | 0.3 | 0.3 | 0.47 | 0.42 | 0.41 | 0.37 | 0.28 | 0.32 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 0.15 | 0.08 | 0.09 | 0.54 | 0.24 | 0.32 | 0.77 | -0.95 | 0.33 | 0.01 | 0.32 | -0.15 | -0.57 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | 0.15 | 0.08 | 0.09 | 0.54 | 0.24 | 0.32 | 0.77 | -0.95 | 0.33 | 0.01 | 0.32 | -0.15 | -0.57 |
| EPS in Rs | 0 | 0 | 0 | 0.01 | 0.01 | 0.01 | 0.02 | -0.02 | 0.01 | 0 | 0.01 | 0 | -0.01 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.68 | 2.12 | 8.54 | 7.86 | 5.87 | 2.47 | 17.21 | 72.64 | 62.45 | 20.28 | 22.96 | 4.97 | 5.02 |
| Expenses | 1.17 | 1.47 | 4.78 | 4.36 | 4.08 | 2.23 | 16.5 | 69.19 | 60.3 | 20.48 | 23.92 | 5.61 | 6.79 |
| Operating Profit | 0.51 | 0.65 | 3.76 | 3.5 | 1.79 | 0.24 | 0.71 | 3.45 | 2.15 | -0.2 | -0.96 | -0.64 | -1.77 |
| OPM % | 30.36% | 30.66% | 44.03% | 44.53% | 30.49% | 9.72% | 4.13% | 4.75% | 3.44% | -0.99% | -4.18% | -12.88% | -35.26% |
| Other Income | 0 | 0.04 | 0 | 0 | 0 | 0 | -0.28 | 0.05 | 0.56 | 1.06 | 1.35 | 1.15 | 1.38 |
| Interest | 0.07 | 0.07 | 0.03 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.1 | 0.07 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 0.34 | 0.55 | 3.73 | 3.5 | 1.79 | 0.24 | 0.43 | 3.5 | 2.71 | 0.86 | 0.39 | 0.51 | -0.39 |
| Tax % | 0% | 1.82% | 0% | 0% | 0% | 0% | 25.58% | 27.71% | 25.09% | 26.74% | 28.21% | 27.45% | — |
| Net Profit | 0.34 | 0.54 | 3.73 | 3.5 | 1.79 | 0.24 | 0.32 | 2.53 | 2.04 | 0.62 | 0.28 | 0.38 | -0.39 |
| EPS in Rs | 0.09 | 0.15 | 1.01 | 0.95 | 0.04 | 0.01 | 0.01 | 0.06 | 0.05 | 0.02 | 0.01 | 0.01 | 0 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1.83 | 1.83 | 1.83 | 1.83 | 19.93 | 19.93 | 19.93 | 19.93 | 39.86 | 39.86 | 39.86 | 39.86 |
| Reserves | 2.41 | 2.94 | 17.54 | 21.04 | 37.31 | 37.54 | 37.86 | 40.39 | 22.49 | 23.12 | 23.39 | 23.77 |
| Borrowings | 0.61 | 0.5 | 0.06 | 0.19 | 0.19 | 0.19 | 0.19 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 0.12 | 0.03 | 0.01 | 3.3 | 6.66 | 7.06 | 16.64 | 33.24 | 17.18 | 10.64 | 0.24 | 0.17 |
| Total Liabilities | 4.97 | 5.3 | 19.44 | 26.36 | 64.09 | 64.72 | 74.62 | 93.56 | 79.53 | 73.62 | 63.49 | 63.8 |
| Fixed Assets | 2.4 | 2.32 | 0 | 0 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0.21 | 0.21 | 0 | 0 | 0 | 0 | 3.06 | 3.22 | 0 | 0 | 9.15 | 9.15 |
| Other Assets | 2.36 | 2.77 | 19.44 | 26.36 | 64.08 | 64.72 | 71.56 | 90.34 | 79.53 | 73.62 | 54.34 | 54.65 |
| Total Assets | 4.97 | 5.3 | 19.44 | 26.36 | 64.09 | 64.72 | 74.62 | 93.56 | 79.53 | 73.62 | 63.49 | 63.8 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -0.07 | -0.04 | -12.94 | 2.23 | -0.5 | -1.01 | 2.36 | 3.57 | 10.54 | 10.16 | -10.21 | -8.2 |
| Investing | -0.11 | 0 | 2.53 | -2.36 | -32.07 | 0.99 | -2.36 | -3.37 | -10.09 | -10.21 | 9.8 | 8.19 |
| Financing | 0.28 | -0.11 | 10.42 | 0.13 | 32.58 | 0 | 0 | -0.19 | 0 | 0 | 0 | 0 |
| Net Cash Flow | 0.1 | -0.16 | 0.02 | 0 | 0.01 | -0.02 | 0.01 | 0.01 | 0.44 | -0.05 | -0.41 | 0 |
| Free Cash Flow | -0.07 | -0.04 | -10.62 | 2.23 | -0.51 | -1.01 | 2.36 | 3.57 | 10.54 | 10.16 | -10.21 | -8.2 |
| CFO/OP | -14 | -6 | -344 | 64 | -28 | -421 | 348 | 132 | 522 | -5,080 | 1,052 | 1,259 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 261 | 456 | 384 | 628 | 1,191 | 3,072 | 601 | 221 | 113 | 59.39 | 0 | 0 |
| Inventory Days | 483 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 46.59 | 846 |
| Days Payable | 46.27 | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Cash Conversion Cycle | 698 | 456 | 384 | 628 | 1,191 | 3,072 | 601 | 221 | 113 | 59.39 | 46.59 | 846 |
| Working Capital Days | 311 | 381 | 384 | 476 | 779 | 2,036 | 249 | 53.71 | 12.8 | -132 | 50.08 | 861 |
| ROCE % | 9.04% | 12.25% | 30.45% | 16.47% | 4.45% | 0.42% | 1.23% | 5.92% | 4.42% | 1.37% | 0.76% | 1.31% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Shree Ganesh Biotech insights
62 extracted metrics + investor summaries across FY10–FY26.
Documents
1
Board Meeting Intimation for Compliance Of Regulation 29 Of SEBI (LODR) Regulations, 2015 - Intimation Of Board Meeting.
4 May - Board meeting on 14 May 2026 to approve audited standalone results for year ended 31 March 2026. 4 May - Board meeting on 14 May 2026 to approve audited standalone results for year ended 31 March 2026.
2
Board Meeting Intimation for Compliance Of Regulation 29 Of SEBI (LODR) Regulations, 2015 - Intimation Of Board Meeting.
4 May - Board meeting on 14 May 2026 to approve audited standalone results for year ended 31 March 2026. 4 May - Board meeting on 14 May 2026 to approve audited standalone results for year ended 31 March 2026.
3
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
23 Apr - Company not a large corporate; no debt disclosure required for FY ended March 31, 2026. 23 Apr - Company not a large corporate; no debt disclosure required for FY ended March 31, 2026.
4
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
9h - Company not a large corporate; no debt disclosure required for FY ended March 31, 2026. 9h - Company not a large corporate; no debt disclosure required for FY ended March 31, 2026.
Frequently Asked Questions about Shree Ganesh Biotech
What does Shree Ganesh Biotech India Ltd do?
Incorporated in 1982, Shree Ganesh Biotech Ltd is engaged in the trading of seeds and bhushi.[1]
Where is Shree Ganesh Biotech India Ltd (539470) listed?
Shree Ganesh Biotech India Ltd trades as SHREEGANESHBIOTECHINDIALTD on the NSE and under code SHREEGANES on the BSE.
Which sector does Shree Ganesh Biotech India Ltd belong to?
Shree Ganesh Biotech India Ltd is classified under the Healthcare sector, in the Biotechnology industry.
What is the market capitalisation of Shree Ganesh Biotech India Ltd?
Shree Ganesh Biotech India Ltd has a market capitalisation of ₹19.5 Cr, which places it in the Small Cap band.
What is the PE ratio of Shree Ganesh Biotech India Ltd?
Shree Ganesh Biotech India Ltd trades at a PE ratio of -49.00, on earnings per share of ₹0.02, against a book value of ₹1.6 per share.
What is the 52-week high and low of Shree Ganesh Biotech India Ltd?
Over the last 52 weeks Shree Ganesh Biotech India Ltd has traded between ₹0.48 and ₹0.8.
What is the Return on Equity (ROE) of Shree Ganesh Biotech India Ltd?
Shree Ganesh Biotech India Ltd reported a return on equity of 0.59%. Its debt-to-equity ratio is 0.00.
Company Information
Incorporated in 1982, Shree Ganesh Biotech Ltd is engaged in the trading of seeds and bhushi.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/539470.md for Shree Ganesh Biotech India Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.